Invesco
TRDA icon

Invesco’s Entrada Therapeutics TRDA Stock Holding History

Invesco’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$529K Buy
41,926
+893
+2% +$10.2K ﹤0.01% 3142
2025
Q4 		$422K Buy
41,033
+11,958
+41% +$101K ﹤0.01% 3264
2025
Q3 		$169K Buy
29,075
+6,682
+30% +$39.1K ﹤0.01% 3599
2025
Q2 		$150K Buy
22,393
+5,702
+34% +$45.9K ﹤0.01% 3584
2025
Q1 		$151K Buy
16,691
+5,187
+45% +$64.6K ﹤0.01% 3568
2024
Q4 		$199K Buy
+11,504
New +$208K ﹤0.01% 3518
2024
Q3 		– Sell
-45,456
Closed -$648K – 3882
2024
Q2 		$648K Buy
45,456
+35,344
+350% +$502K ﹤0.01% 3164
2024
Q1 		$143K Sell
10,112
-7,184
-42% -$102K ﹤0.01% 3703
2023
Q4 		$261K Buy
+17,296
New +$256K ﹤0.01% 3477
2022
Q4 		– Sell
-95,209
Closed -$1.5M – 4066
2022
Q3 		$1.5M Buy
+95,209
New +$1.21M ﹤0.01% 2755

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco's TRDA Position: Q1 2026 in Review

Invesco increased its Entrada Therapeutics (TRDA) stake by 2.2% in Q1 2026, buying an estimated $10.2K and bringing the position to 41,926 shares worth $529K. The position accounts for ﹤0.01% of the portfolio, ranked #3142.

Invesco first reported a position in TRDA in Q3 2022 and has held it in 10 quarters since. The position peaked at $1.5M in Q3 2022. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Invesco held 41,926 shares of Entrada Therapeutics worth $529K as of Q1 2026.
  • Invesco bought 893 Entrada Therapeutics shares in Q1 2026, an estimated $10.2K.
  • Entrada Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3142 holding.
  • Invesco first reported a position in Entrada Therapeutics in Q3 2022 and has held it in 10 quarters since.
  • Invesco's Entrada Therapeutics position peaked at $1.5M in Q3 2022.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.